The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An interim evaluation of efficacy and safety of the combination of panitumumab, gemcitabine, and irinotecan in patients with advanced or metastatic cholangiocarcinoma: A phase II study.
Weijing Sun
Research Funding - Amgen
Davendra Sohal
No relevant relationships to disclose
Kristine Mykulowycz
No relevant relationships to disclose
Ursina R. Teitelbaum
No relevant relationships to disclose
Nevena Damjanov
No relevant relationships to disclose
Bruce J. Giantonio
No relevant relationships to disclose
Mary Carberry
No relevant relationships to disclose
Paul Stephen Wissel
No relevant relationships to disclose
Mona Jacobs-Small
No relevant relationships to disclose
Peter James O'Dwyer
No relevant relationships to disclose